



The two major autoimmune diseases demonstrating activated 
partial thromboplastin time (APTT) prolongation and normal 
prothrombin time (PT) on coagulation screening are antiphospholipid 
(aPL) antibody syndrome (APS) and acquired hemophilia. APTT 
cross‑mixing test demonstrates an inhibitory pattern in both diseases, 
and the diagnoses are made according to clinical findings and the 
measurement of aPL antibodies or coagulation factor activities. 
Several cases of coexistent APS and acquired hemophilia have 
been reported; however, the mechanisms underlying the concurrent 
development of both diseases are yet to be well clarified. Herein, 
we report a case of autoimmune hemolytic anemia (AIHA) with 
aPL antibodies, in which the existence of acquired hemophilia 
was excluded by APTT cross‑mixing test with a recombinant 
factor VIII product.
Case report
An 88‑year‑old female presented to the outpatient clinic in August 
2013. Her chief complaint was a 2-month history of stridor on walking. 
She had a medical history of mucosa‑associated lymphoid tissue 
lymphoma of the lung from 71 years of age and anemia diagnosed at 
75 years of age. Plain chest radiography demonstrated cardiomegaly 
and pericardial effusion. At the time of admission, generalized pallor 
and anemic conjunctivae were noted. Slight lower limb edema was 
also detected. No other abnormalities were observed. She was not 
administrated heparin or anticoagulant medications. Laboratory testing 
at this time revealed the following: white blood cell (WBC) count, 
2.78 × 109/l; hemoglobin (Hb), 6.4 g/dl; mean corpuscular volume 
(MCV), 109.9 fl; reticulocytes, 7.2 × 104/ml (normal range, 2‑8 × 104/ml); 
platelet count, 110 × 109/l. These tests also demonstrated the existence 
of macrocytic anemia with normal reticulocyte count. Serological 
testing was abnormal as follows: lactose dehydrogenase (LD), 
402 IU/l (normal range, 119-229 IU/l); and haptoglobin, < 10 mg/ dl. 
Immunological testing results were as follows: immunoglobulin (Ig)G 
1459 mg/dl (870-1700 mg/dl); IgA, 348 mg/dl (110-410 mg/ dl); 
IgM, 306 mg/dl (35-220 mg/dl); CH50, 14 U/ml (32-58 U/ml); 
C3, 27 mg/dl (65-135 mg/dl); and C4, 2 mg/dl (13-25 mg/dl). These 
findings were indicative of accelerated IgM antibody production and 
hemolysis with consumption of complements. Direct antiglobulin test 
was positive for C3d and negative for IgG. These results indicated 
AIHA. Autoantibody testing demonstrated an antinuclear antibody titer 
of 1:80 and the absence of anti‑DNA antibodies. Coagulation testing 
revealed the following: APTT, 86 s (24-39 s); PT, 14.0 s (10.5-14.0 s); 
fibrinogen, 244 mg/dl; and antithrombin, 76.2%. These findings 
demonstrated severe prolongation of APTT. APTT cross‑mixing 
test with patient plasma and normal plasma demonstrated an 
inhibitory pattern (Fig. 1 A). Antibody test results related to aPL were 
as follows: lupus anticoagulant (LAC) by diluted Russell’s viper venom 
time (dRVVT), 2.18 (< 1.3); anticardiolipin antibody (IgG), ×10 titer 
(< 10); and anticardiolipin b2GPI antibody, 11.2 U/ml (< 3.5 U/ ml). 
We performed the platelet neutralization procedure (PNP) as 
a confirmatory test for phospholipid dependence, i.e., an aliquot of 
lysed platelets in the frozen condition, after washing with normal 
saline, was added to patient plasma to neutralize the effect of aPL 
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antibodies. APTT changed its value from 90.2 s to 64.5 s by the PNP 
process, the result thus supporting the influence of aPL antibodies on 
APTT-based assay. The dRVVT was positive at 4 months after the 
diagnosis, confirming that her condition met the laboratory criteria 
of aPL antibody syndrome without clinical manifestation [1]. Specific 
factor assay for coagulation factors VIII, IX, XI, and XII were performed 
by the one‑stage APTT‑based assay. Factor XIII and von Willebrand 
factor were measured by chromogenic assay and macroscopic 
platelet agglutination assay, respectively. To conduct the one‑stage 
APTT-based assay, coagulation factor-deficiency plasma for factors 
VIII, IX, XI, and XII (HemosIL® series, Instrumentation Laboratory, 
Bedford, MA, USA) and APTT reagent (HemosIL® Synthasil APTT, 
Instrumentation Laboratory) were used. Coagulation factor VIII and IX 
inhibitors were measured by the Bethesda method by the outsourcing 
company SRL, Inc. (Tokyo, Japan). The results of coagulation 
factor activity were as follows: factor VIII, 7%; factor IX; < 1%; von 
Willebrand factor, 119%; factor XI, 3%; factor XII, 4%; and factor XIII, 
70%. Inhibitory coagulation factors were additionally tested, with 
results as follows: factor VIII inhibitor, 16 biological units (BU)/ml; and 
factor IX inhibitor, 23 BU/ml. These results indicated a high level 
of both  coagulation factor inhibitors. The prothrombin antibody titer 
was 8 U/ ml (< 10 U/ml), and von Willebrand factor-cleaving protease 
(ADAM-TS13) activity was 74%. Bone marrow aspiration testing 
demonstrated no specific abnormalities. Brain magnetic resonance 
imaging showed brain atrophy corresponding with her age, with no 
obvious infarction. According to these results, AIHA with laboratory 
APS was diagnosed [1]. LAC hypoprothrombin syndrome (LH-HPS) 
was excluded due to the absence of prothrombin antibody.
The patient’s clinical course is shown in figure 2. Therapeutic 
intervention for AIHA was performed, with oral prednisolone (PSL) 
therapy (15 mg/day) started in August 2013, considering her 
advanced age. Diuretics were initiated to treat heart failure. After 
starting PSL therapy, hemolysis and anemia gradually improved. 
In order to avoid side effects associated with PSL, the dose of PSL 
was reduced gradually to 8 mg/day by replacing with azathioprine. 
At the beginning of 2014, the hemoglobin level had increased to 
> 8 g/dl without red blood cell transfusion; however, the complement 
titer, coagulation factor IX activity, and inhibitor level of coagulation 
Fig. 1.
A. APTT cross-mixing test with patient plasma and normal plasma. X-axis shows mixing proportions. Patient, patient plasma. Nor-
mal, normal plasma.
B. Purpura affecting the extremities (arrow).
C. APTT cross-mixing test with patient plasma and product. The result from patient plasma mixed with recombinant factor VIII prod-
uct is shown by the dotted line, and the result from patient plasma mixed with the immunoglobulin product is shown by the solid
line. X-axis shows mixing proportions. Factor VIII, recombinant factor VIII product. Ig, immunoglobulin product.
D. Factor IX activity (solid graph) and the inhibitor titer of factor IX (bar graph). Original patient plasma, or patient plasma and re-
combinant factor VIII product (5:5) were tested. Coagulation Factor IX activity increased to 10% when patient plasma was mixed with
the recombinant factor VIII product; rFVIII, recombinant factor VIII product 
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factor IX remained unchanged during the patient’s clinical course 
(Fig. 2). Purpura developed on the right upper arm and left legs in 
February 2014 (Fig. 1 B), with similar purpura intermittently observed 
on the extremities. Accordingly, a hemostatic agent was used to 
continuously treat her purpura.
To investigate the cause of emerging purpura, we considered the 
possibility of coexisting acquired hemophilia. We particularly focused 
on acquired hemophilia B as coagulation factor IX had the lowest titer. 
We supposed that recombinant factor VIII product, where factor IX 
did not exist, could bind to aPL antibodies, resulting in the decrease 
of the aPL antibodies by neutralization in the test tube study. We 
hypothesized that factor IX activity might emerge by elimination of aPL 
antibodies with recombinant factor VIII product, while factor IX activity 
might not increase in the existence of acquired hemophilia B disease 
in the same study. APTT cross‑mixing test [2] with recombinant factor 
VIII product instead of control plasma was performed, in which 
we attempted to remove the effect of aPL antibodies. Kogenate® 
FS Bio‑Set® was purchased from Bayer Pharmaceuticals Inc. as the 
recombinant factor VIII product, and Venilon® was kindly provided by 
Teijin Pharma Limited (Tokyo, Japan) as the immunoglobulin product. 
The immunoglobulin product was used as the control mixing agent 
by comparing with the recombinant factor VIII product. The product 
containing 250 IU of Kogeneate® FS Bio-Set® was dissolved in 
25 ml of water, and 500 mg (1 vial) of Venilon® was dissolved 
in 100 ml of water. Coagpia® APTT-N (Sekisui Medical, Co., Ltd., 
Tokyo, Japan) was prepared as the reagent for the APTT test, and 
APTT was measured with a Blood Coagulation Analyzer Coapresta® 
2000 (Sekisui Medical). This analyzer was designed to perform 
a fully automated coagulation assay based on photo‑optical end point 
detection, possessing a multidiluting function with a maximum seven‑ 
point dilution [3]. Automated cross‑mixing test was performed using 
the patient plasma and reagent (with the five concentration ratios 
of 10:0, 8:2, 5:5, 2:8, and 0:10), the results of which were expressed 
as a graph pattern, measured using the APTT‑N reagent. The result 
of the APTT cross-mixing test is shown in figure 1 C. The APTT 
value of her plasma mixed with the immunoglobulin product increased 
gradually in proportion with the dilution, indicating no neutralization 
effect by the immunoglobulin product. On the contrary, the APTT 
value of her plasma mixed with an equal amount of the recombinant 
factor VIII product decreased to within the normal range, indicating 
that the recombinant factor VIII product had a neutralizing effect on 
aPL antibodies in the APTT system. When measuring coagulation 
factor IX activity and factor IX inhibitor titers by using mixed sample of 
plasma and the recombinant factor VIII product in equal proportions, 
factor IX activity increased to 10% level, while the factor IX inhibitor 
titer did not obviously change (Fig. 1 D). These results indicate that 
the recombinant factor VIII product had the ability to diminish the false‑ 
negative reaction caused by the aPL antibodies on the APTT analysis 
system. We therefore excluded acquired hemophilia B complication 
by confirming the emergence of factor IX activity in the test tube study.




AIHA is an autoimmune disease that may occur as a consequence 
of another autoimmune disease, termed secondary AIHA, or as 
a complication of other autoimmune diseases. AIHA accompanied by 
APTT prolongation was diagnosed in the present case. In general, 
APTT cross‑mixing test is adapted as an initial diagnostic test 
for cases with prolonged APTT and normal PT. The diagnosis is 
determined according to the pattern of APTT cross‑mixing results, 
i.e., the correction status of APTT on mixing equal volumes of patient 
and normal plasma. When no correction is observed, the differential 
diagnosis, including APS or acquired hemophilia, is determined 
according to clinical findings, aPL antibody titers, and coagulation 
factor activity. The clinical evaluation of this patient revealed the 
presence of aPL antibodies, as the present case had no history of 
vascular thrombosis or pregnancy but met the laboratory criteria of 
aPL antibody syndrome [1].
Regarding the coagulation test performed in the present case, several 
intrinsic coagulation factor activities, particularly factor IX, showed 
remarkable decreases, and the inhibitor titers for coagulation factor 
VIII and IX were elevated. When detecting decreases in the activity of 
numerous coagulation factors or the presence of coagulation factor 
inhibitors, the false phenomenon caused by aPL antibodies due to 
modulation of the APTT system should be considered [2, 4]. As the 
APTT system depends on phospholipids, decreases in coagulation 
factors or the detection of coagulation inhibitors may be attributable 
to inhibition of phospholipid activity by aPL antibodies. One solution 
is to use the dRVVT test [5, 6]; however, careful consideration is 
required to arrive at the correct diagnosis. To confirm the phospholipid 
dependence, PNP or hexagonal phase phospholipid neutralization 
procedure (Staclot® LA) is generally used, in which we selected PNP. 
In terms of the differential diagnoses for aPL syndrome and acquired 
hemophilia, cases with the coexistence of aPL syndrome and 
acquired hemophilia have been reported in recent years [7–10], in 
most of which the bleeding symptom was the major event irrespective 
of fulfillment of the criteria for aPL syndrome. The identification of the 
coexistence of aPL and anti‑coagulation factor antibodies is limited 
by the APTT‑dependent diagnostic system [11, 12]. The present case 
demonstrated the presence of aPL antibodies with purpura rather 
than thrombotic symptoms. The absence of numerous intrinsic 
coagulation factors, particularly factor IX (< 3% activity), with a high 
level of coagulation factor IX inhibitor, should be considered when 
assessing for acquired hemophilia B. If acquired hemophilia is 
present, an antibody to coagulation factor IX should be suspected 
as the most likely cause. To determine the presence of factor IX 
antibodies, we attempted the APTT cross‑mixing test with patient 
serum and a recombinant factor VIII product instead of the control 
plasma, the result of which demonstrated normalization of the 
APTT with mixing of equal sample volumes. The APTT cross‑ 
mixing test with patient plasma and the immunoglobulin product as 
a control demonstrated no normalization of the APTT (Fig. 1 C). 
This result indicates that the recombinant factor VIII product had the 
ability to normalize the APTT of the patient sample. When using 
equal volumes of patient plasma and the recombinant factor VIII 
product, factor IX activity increased to 10%, while the inhibitor 
titer of factor IX remained at 24 BU/ml in the revised calculation 
(Fig. 1 D). As the recombinant factor VIII product contained no other 
coagulation factors, the increasing factor IX activity indicates that the 
factor IX activity of the initial patient sample was a false‑negative 
result and the recombinant factor VIII product had the ability to 
correct this false‑negative phenomenon. In other words, recombinant 
factor VIII product may lead to the repair of incorrect results from 
the APTT‑dependent diagnostic system in the presence of aPL 
antibodies.
We showed no complication of hemophilia B in the present case; on 
the other hand, we did not exactly show whether hemophilia A was 
complicated or not. However, acquired hemophilia B was more likely 
the cause than acquired hemophilia A if considering the complication 
of acquired hemophilia, due to the fact that the level of coagulation 
factor VIII remained as 7%, which was higher than the level of 
factor IX activity, and the inhibitor titer of coagulation factor VIII was 
less than that of coagulation factor IX.
Chromogenic assay is another method for the evaluation of 
coagulation factors, including factor VIII and IX. There are several 
reports on the comparison between one‑stage APTT‑based assay 
and chromogenic assay for assessing coagulation factor levels in 
patients with anti‑PL antibodies, in some of which the chromogenic 
assay is recommended. The one‑stage APTT‑based assay may be 
influenced by nonspecific inhibitors [13], and Chandler et al. report 
that chromogenic assay is better than one‑stage APTT‑based assay 
for measuring factor VIII activity in lupus inhibitor‑containing samples 
[14]. In addition, a few cases showed that aPL antibody influenced 
the one‑stage APTT‑based assay but not the chromogenic assay 
[15], implying that the chromogenic assay is an optimal test for 
evaluating coagulation factor VIII and IX activities in patients with 
anti‑PL antibodies.
We concluded that the present case did not have acquired hemophilia 
B. To the best of our knowledge, this is the first report of the use of the 
APTT cross‑mixing test using coagulation factor products, including 
recombinant factor VIII, as a dilution reagent instead of normal plasma. 
As the present report involves a single case, further studies are 
required to clarify the effects of autoantibodies in patients with APS.
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